However, deposition of C3 fragments on PNH RBCs is detectable in patients treated with eculizumab, suggesting that EVH is a source of ongoing hemolysis in C5 inhibitor-treated patients with PNH [4, 23]. This evidence concerns the gene C5 and paroxysmal nocturnal hemoglobinuria.